ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.1429.

Several analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Tuesday, November 4th.

ProQR Therapeutics Stock Up 9.8%

ProQR Therapeutics stock opened at $2.36 on Thursday. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $3.97. The firm has a market capitalization of $248.30 million, a price-to-earnings ratio of -5.02 and a beta of 0.16. The firm has a 50-day moving average price of $2.38 and a two-hundred day moving average price of $2.16.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $7.05 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. Research analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Trading of ProQR Therapeutics

Institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc bought a new stake in shares of ProQR Therapeutics during the 1st quarter worth $2,461,000. Affinity Asset Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock valued at $4,368,000 after purchasing an additional 459,512 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of ProQR Therapeutics by 73.2% in the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after purchasing an additional 277,749 shares during the period. Two Sigma Investments LP increased its stake in ProQR Therapeutics by 86.3% in the 3rd quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 193,260 shares in the last quarter. Finally, Palo Alto Investors LP purchased a new position in ProQR Therapeutics in the 3rd quarter worth about $402,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).